Skip to content
AnalystLens

Insmed 8-K Report, Agreement Terminated (Nov 19, 2024)

Reports
Material Agreements
Filing Date
Filed November 19, 2024
Period End
November 18, 2024
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed November 19, 2024. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated disclosed in this Form 8-K, under Item 1.02 (Termination of a Material Definitive Agreement), that it terminated its at-the-market Sales Agreement with Leerink Partners LLC, as agent, on November 18, 2024.

The termination was effective immediately. The agreement had been entered into on February 22, 2024, and allowed the company to offer and sell shares of its common stock, par value $0.01a per share, with an aggregate offering price of up to $500,000,000 through Leerink. The filing states that no shares had been issued or sold under the agreement since September 30, 2024.

The company also states it is not subject to any termination penalties related to ending the agreement. For investors, the filing indicates that the company no longer has access to this specific equity sales facility, and that the $500,000,000b capacity under it is no longer available. The full text of the agreement was filed previously as Exhibit 10.1 to the company's Current Report on Form 8-K filed February 22, 2024, and this filing refers to that exhibit for the complete terms.

02—Key points

Key Highlights

  1. Insmed terminated its Sales Agreement with Leerink Partners LLC, as agent, on November 18, 2024, effective immediately.
  2. The terminated agreement, entered into February 22, 2024, covered sales of common stock (par value $0.01 per share) with an aggregate offering price of up to $500,000,000.
  3. No shares of common stock were issued or sold under the agreement since September 30, 2024.
  4. The company states it is not subject to any termination penalties related to ending the agreement.
  5. The filing is a disclosure under Item 1.02 (Termination of a Material Definitive Agreement).
  6. The complete agreement was previously filed as Exhibit 10.1 to the company's February 22, 2024 Form 8-K.

03—Questions

Frequently Asked Questions

  1. What was the agreement that Insmed terminated?

    It was a Sales Agreement entered into on February 22, 2024, with Leerink Partners LLC acting as agent. It allowed Insmed to offer and sell its common stock, from time to time, with an aggregate offering price of up to $500,000,000 through Leerink.

  2. When did the termination take effect?

    Insmed terminated the Sales Agreement on November 18, 2024, and the termination was immediately effective.

  3. Did Insmed sell any shares under this agreement before it was terminated?

    The filing states that no shares of common stock have been issued or sold pursuant to the agreement since September 30, 2024.

  4. Does Insmed owe any penalties because of the termination?

    No. The company states it is not subject to any termination penalties related to the termination of the agreement.

  5. Where can investors find the full terms of the agreement?

    The full text of the Sales Agreement is filed as Exhibit 10.1 to Insmed's Current Report on Form 8-K filed with the SEC on February 22, 2024.

04—Continue

← View all 8-K filings